Clinical Trial: EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617805) titled 'EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC' on May 25.

Brief Summary: This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2. The study is designed as a biomarker-enriched, open-label, non-randomized trial with a dose-escalation safety lead-in followed by an expansion cohort at the recommended Phase 2 dose (RP2D).

Study Start Date: March 02

Study Type: INTERVENTIONAL

Condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Biomarke...